We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NIH Reports Encouraging Results From Calquence Trial
NIH Reports Encouraging Results From Calquence Trial
Results from preliminary research show that AstraZeneca’s blood cancer treatment Calquence (acalabrutinib) provides a benefit in hospitalized COVID-19 patients.